bioAffinity Technologies, Inc.
BIAF · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 13.9% | -31.5% | -16% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 27% | 19.9% | 26.2% | 22.3% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -340.9% | -307.9% | -133.9% | -126.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -349.3% | -319.9% | -143.5% | -134.4% |
| EPS Diluted | -4.74 | -5.07 | -4.8 | -6 |
| % Growth | 6.5% | -5.6% | 20% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |